Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline M Tanner

Showing results (171-180 of 207) with videos related to

Pageof 21
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2020
Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease PenetranceMarta San Luciano, Caroline M Tanner, Cheryl Meng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
Annals of Clinical and Translational Neurology|April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined SynucleinopathyDaniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 11, 2017
Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's diseaseNaomi P Visanji, Grace S Bhudhikanok, Tiago A Mestre, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Pageof 21

Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2020
Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease PenetranceMarta San Luciano, Caroline M Tanner, Cheryl Meng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
Annals of Clinical and Translational Neurology|April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined SynucleinopathyDaniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 11, 2017
Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's diseaseNaomi P Visanji, Grace S Bhudhikanok, Tiago A Mestre, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Pageof 21